1 / 21

Assessing risk in kidney transplantation: Back to Complement ?

Assessing risk in kidney transplantation: Back to Complement ?. D. Glotz 2013. TOTAL. ANTI-HLA. 195 negative crossmatch: 8 failed (4,1%). 225 patients. 30 positive crossmatch: 24 failed (80%). Luminex. Solid phase assays. (CXM neg). ELISA/CDC in pregraft sera. Ac +. 100. 100. Ac +.

brendy
Download Presentation

Assessing risk in kidney transplantation: Back to Complement ?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Assessing risk in kidney transplantation: Back to Complement ? D. Glotz 2013

  2. TOTAL ANTI-HLA

  3. 195 negative crossmatch: 8 failed (4,1%) 225 patients 30 positive crossmatch: 24 failed (80%)

  4. Luminex

  5. Solid phase assays (CXM neg) ELISA/CDC in pregraft sera Ac + 100 100 Ac + 80 80 60 60 Ac - 40 40 Ac - 20 20 0 0 0 10 20 30 0 10 20 30 ELISA (P < 0,05) CDC (ns) Anti-HLA Abs and prevalence of rejection Dalla Vecchia, Transpl 97

  6. 12 3 5 13 5 2 88 13 3 73 28 3 p=0,2 p<0,0009 Solid phase assays ELISA CDC <10% 10-50% >50% <10% 10-50% >50% Graft loss No graft loss 124 Tx 1991-1994 Monteiro Transpl. 97

  7. TOTAL DSA ANTI-HLA

  8. Distribution of donor specific anti-HLA activity depending of the DSA detection technique Lefaucheur JASN 2010

  9. Incidence ofHumoral Rejection General population :8,9% Patients DSA+ :34,9%(p<0,00001) Patients DSA- :3,1% Lefaucheur AJT 2007/2008

  10. Low positive predictive value….

  11. Limits of SAFB techniques Low PPV

  12. TOTAL DSA C-binding subclass DSA ANTI-HLA

  13. C1q-binding antibodies Prediction of AMR on peri-Tx serum 18 pediatric heart Tx Chin, JHLT 2011

  14. C1q binding DSA study • Observational study • Necker and Saint-Louis • 1016 patients Tx 2005-2009

  15. Study design Tx 01/2005-06/2009 1016 pts 01/2012 1 year Rejection Clinical characteristics GFR Bx DSA DSA-C1q GFR Bx DSA DSA-C1q Follow-up 4.4±09yr Pts/graft survival GFR Loupy, NEJM 2013

  16. Study demographics Loupy, NEJM 2013

  17. POST-TX DSA: OUTCOME DSA+/C1q+ = Higher risk of graft loss Loupy, NEJM 2013

  18. POST-TX DSA: OUTCOME Loupy, NEJM 2013

  19. Multivariate analysis

  20. Clinical value of the C1q assay For graft loss For ABMR Loupy, NEJM 2013

  21. Assessing risk in kidney transplantation: Back to Complement ! D. Glotz 2013

More Related